If you have been reading about synthetic peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-07-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
== External links == Histology at utmb.edu Histology image: 36_02 at the University of Oklahoma Health Sciences Center - "ureter" Histology image: 37_02 at the University of Oklahoma Health Sciences Center - "urinary bladder" Anatomy Atlases – Microscopic Anatomy, plate 02.24 - "Transitional Epithelium", Ureter Histology at KUMC urinary-renal16 "ureter" www.urothelium.com is an online resource for information about Human Urothelium and the "Biomimetic Urothelium" Archived 2011-02-01 at the Wayback Machine Urothelium at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Histology at qmul.ac.uk Archived 2011-07-21 at the Wayback Machine Diagram at umich.edu Archived 2006-09-10 at the Wayback Machine Histology at wisc.edu Archived 2008-06-10 at the Wayback Machine
While this process depletes glutathione initially, it paradoxically stimulates increased glutathione synthesis. The compound's anti-proliferative effects appear particularly pronounced in cancer cells with compromised mitochondrial function, suggesting a relationship between mitochondrial fitness and therapeutic efficacy.
On the weekend of September 23–25, 2022, a delegation of the Grand Lodge of Veracruz, from Veracruz, Veracruz, traveled to Havana, where the Grand Lodge of Cuba recognized that body as "regular and correct" in a ceremony at the National Temple. Grand Master Alfonso Vidal, with the Grand Commander of the Supreme Council of Cuba, José Ramón Viñas Alonso, presented certificates of friendship and recognition to the Mexican delegation. In what was called an act of fraternal friendship, the Grand Lodge of Veracruz invited the Grand Master Alfonso Vidal to tour their Grand Lodge in Mexico and participate in a Masonic ceremony there. On December 5, 2022, the National Temple hosted the 163rd anniversary celebration of the founding of the Grand Lodge of Colon in 1859. Grand Orator Luis Steve Ocaña guided the congregation through the history of Cuban Freemasonry since the 19th century, and told the congregation of hundreds of Freemasons in his liturgy that: "Today, the fight for the homeland is with the most important weapon that Freemasons carry, which is the most lofty thought with which we must act to stop seeing everywhere the lament of the loss of values in society.... I believe that we masons should talk about politics, since it is the fundamental rule that governs society, we must talk and, in addition, look for a way to do politics." Days later, Alfonso Vidal was interrogated again by Agent Poll from the State Security Unit. This interrogation lasted for twelve hours.
Sources: en.wikipedia.org
== Victim == Buzhu's father emigrated to the Netherlands from Morocco in the 1950s and worked in a Dutch mine. His mother later rejoined his father and the couple settled in Utrecht. The father then opened a butcher shop in Amsterdam and provided financial stability to the family. After his father died, Buzhu went into organized crime alongside other Moroccans who had emigrated to the Netherlands. In order to hide his illicit wealth, Buzhu pretended his money was earned through real estate investment. His real source of income was smuggling large quantities of drugs from Morocco. In the 1990s, he was convicted by Dutch police of possession of illegal firearms and participating in torture. On 24 June 2015, a friend of Buzhu's went to the police in Driebergen claiming he found a tracking beacon underneath his vehicle. Buzhu also came forward and claimed that the case was related to the kidnapping of coffee shop owner in 2009. The police closed the case without a thorough investigation. A few days later, he returned to the police station and filed a complaint against Ridouan Taghi and his right-hand man Saïd Razzouki for death threats. Further investigations led Buzhu to identify several organized criminals in the Dutch drug trade, with his statements giving rise to the 26Koper investigation. In 2016 his friend Ranko Scekic and another friend were the victims of an attempted assassination in Utrecht by Taghi's hitmen for their allegiance with Buzhu. The assassination was eventually called off due to heavy police presence in the neighborhood.
For instance, disease-modifying medications for rheumatoid arthritis or surgery for traumatic acute carpal tunnel syndrome. There is insufficient evidence to recommend gabapentin, non-steroidal anti-inflammatories (NSAIDs), yoga, acupuncture, low level laser therapy, magnet therapy, vitamin B6 or other supplements.
can be easily calculated without the need of calibration or gas standards. Furthermore, it gets obvious that the overall sensitivity of a PTR-MS instrument is dependent on the reagent ion yield. Fig. 1 gives an overview of several published (in peer-reviewed journals) reagent ion yields during the last decades and the corresponding sensitivities.
This difference was characterised by an attenuated EEG power density within slow frequencies (<4 Hz) following flmodafinil treatment, though both compounds increased power density relative to placebo. In contrast to modafinil, flmodafinil is not an inducer of the cytochrome P450 CYP3A4 or CYP3A5 enzymes.
Sources: en.wikipedia.org
On August 6, 1945, the uranium-type nuclear weapon codenamed "Little Boy" was detonated over the Japanese city of Hiroshima with an energy of about 15 kilotons of TNT (63,000 gigajoules), destroying nearly 50,000 buildings (including the headquarters of the 2nd General Army and Fifth Division) and killing approximately 70,000 people, including 20,000 Japanese combatants and 20,000 Korean slave laborers. Three days later, on August 9, a plutonium-type nuclear weapon codenamed "Fat Man" was used against the Japanese city of Nagasaki, with the explosion equivalent to about 20 kilotons of TNT (84,000 gigajoules), destroying 60% of the city and killing approximately 35,000 people, including 23,200–28,200 Japanese munitions workers, 2,000 Korean slave laborers, and 150 Japanese combatants. The industrial damage in Nagasaki was high, partly owing to the inadvertent targeting of the industrial zone, leaving 68–80 percent of the non-dock industrial production destroyed. The U.S., despite not having a third device ready to be dropped, gave Japan one last warning that there would be another bombing if they did not surrender, and the target would be Tokyo. Six days after the detonation over Nagasaki, Japan announced its surrender to the Allied Powers on August 15, 1945, signing the Instrument of Surrender on September 2, 1945, officially ending the Pacific War and, therefore, World War II, as Germany had already signed its Instrument of Surrender on May 8, 1945, ending the war in Europe.
== Awards == 1999 - March of Dimes Basil O’Connor Award 1999 - Frederick J. Terman Junior Faculty Award 1999 - Rita Allen Foundation Scholar 1999 - American Heart Association New Investigator Award 2000 - Cancer Research Institute New Investigator Award 2001 - Pew Scholar 2002 - Keck Distinguished Medical Scholar 2004 - Established Investigator of the American Heart Association 2012 - Elected to National Academy of Sciences 2013 - NIHMERIT award 2015 - Member of Mathematical Sciences Jury for the Infosys Prize 2016 - Elected to National Academy of Medicine 2024 - Passano Award
For example, the nitrile group of the competitive PDE-3 inhibitor milrinone forms an affinity-relevant hydrogen bond via a histidine residue located at the binding site of these phosphodiesterases. Nitriles can form a coordinative bond with calcium cations, which is essential for the activity of calcium antagonists of the verapamil type. These agents inhibit calcium influx by forming, through ligand–calcium complex chemistry, a salt bridge with one of the glutamic acid residues in the selectivity filter within the pore of the calcium channel. Verapamil is used in cardiovascular diseases such as arterial hypertension and angina pectoris. Nitrile substituents decrease the electron density of aromatic compounds through a strong inductive effect. In this manner, π-π interactions between a drug molecule and suitable amino acid residues of a target protein, such as phenylalanine, tyrosine, tryptophan, and histidine, are modulated. Such π-π interactions are observed with the aromatase inhibitors letrozole and anastrozole, which act as antiestrogens and are used in breast cancer. Many androgen receptor antagonists contain a markedly electron-deficient aromatic ring, which is particularly important for supramolecular receptor binding. In bicalutamide, enzalutamide, and other analogs used to treat prostate cancer, a nitrile group contributes to this electronic effect. In some cases, nitriles form a reversible yet pharmacologically relevant covalent bond with a target molecule.
== Diagnosis == Substance use disorders can be confused with other psychiatric disorders. There are diagnoses for substance-induced mood disorders and substance-induced anxiety disorders and thus such overlap can be complicated. For this reason, the DSM-IV advises that diagnoses of primary psychiatric disorders not be made in the absence of sobriety (of a duration sufficient to allow for any substance-induced post-acute-withdrawal symptoms to dissipate) up to 1 year.
Superficial burns may be managed with little more than simple pain medication, while major burns may require prolonged treatment in specialized burn centers. Cooling with tap water may help pain and decrease damage; however, prolonged cooling may result in low body temperature. Partial-thickness burns may require cleaning with soap and water, followed by dressings. It is not clear how to manage blisters, but it is probably reasonable to leave them intact if small and drain them if large. Full-thickness burns usually require surgical treatments, such as skin grafting. Extensive burns often require large amounts of intravenous fluid, due to capillary fluid leakage and tissue swelling. The most common complications of burns involve infection. Tetanus toxoid should be given if not up to date. In 2015, fire and heat resulted in 67 million injuries. This resulted in about 2.9 million hospitalizations and 176,000 deaths. Among women in much of the world, burns are most commonly related to the use of open cooking fires or unsafe cook stoves. Among men, they are more likely a result of unsafe workplace conditions. Most deaths due to burns occur in the developing world, particularly in Southeast Asia. While large burns can be fatal, treatments developed since 1960 have improved outcomes, especially in children and young adults. In the United States, approximately 96% of those admitted to a burn center survive their injuries. The long-term outcome is related to the size of burn and the age of the person affected.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.